Fig. 4From: Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancerSafety and biocompatibility evaluation of the nanomedicine. (a) CCK-8 assay analyzing the effects of free DDP, Lipo@DDP, Lipo@DDP@miR-219a-5p, and Lipo@DDP@miR-219a-5p@FA on the viability of BEAS-2B cells; (b) Hemolysis assay examining the blood compatibility of the nanocarriers, with the first and fifth tubes representing negative and positive controls, respectively. *p < 0.05Back to article page